NASDAQ
Pacific Biosciences of California, Inc. (PACB)
♥ 555 Thanks from members
Pacific Biosciences of California, Inc. (PACB) faces extreme market pressure, highlighted by a falling stock price, downwardly revised 2026 revenue guidance, a leadership transition from Christian Henry to Mark Van Oene, and delayed cash-flow breakeven pushed out to 2028 despite rollout of SPRQ-Nx chemistry.